Medicines Development For Global Health
Clinical trials sponsored by Medicines Development For Global Health, explained in plain language.
-
Massive trial tests safer river blindness drug in nearly 13,000 people
Disease control CompletedThis study tested the safety of a single dose of moxidectin compared to ivermectin in nearly 13,000 people living in areas where river blindness is common. Some participants also received albendazole for a related infection. The goal was to see if moxidectin causes fewer or less …
Phase: PHASE3 • Sponsor: Medicines Development for Global Health • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
River blindness drug dose for kids tested in new study
Knowledge-focused CompletedThis study tested a single dose of moxidectin in 36 children aged 4 to 17 years living in areas with river blindness (onchocerciasis). The goal was to find a dose for children 4-11 years that works as well as the 8 mg dose used in older people. Researchers measured drug levels in…
Phase: PHASE1 • Sponsor: Medicines Development for Global Health • Aim: Knowledge-focused
Last updated May 26, 2026 10:07 UTC